drugset / Trial / NCT05501860

A Safety Study of of AG-920 Sterile Topical Ophthalmic Solution

NCT05501860

Phase 3 Completed 249 enrolled American Genomics, LLC
RandomizedParallel-groupTriple-blindSupportive care

Summary

A Phase 3, randomized, placebo-controlled, double-masked, parallel study in healthy subjects. It is designed to evaluate the ocular safety of a single topical ocular administration of AG-920 sterile topical ophthalmic solution compared to placebo..

Timeline

Start
2022-07-30
Primary completion
2022-12-07
Completion
2022-12-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Articaine Other / unclassified Topical

Indications

No indication recorded.